Seroatlas · Human Serome Atlas

STPG4

Protein STPG4

Also known as: C2orf61, FLJ40172, STPG4_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8N801
Gene: STPG4
Ensembl: ENSG00000239605
Chromosome: 2
Canonical length: 248 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Cytosol

OverviewNCBI Gene

Predicted to enable chromatin binding activity and histone binding activity. Predicted to be involved in epigenetic programing of male pronucleus. Predicted to act upstream of or within pyrimidine-containing compound catabolic process. Predicted to be located in cytoplasm and nucleus. Predicted to be active in female pronucleus; germinal vesicle; and male pronucleus. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

248 residues, UniProt reviewed canonical sequence.

>Q8N801|STPG4
     1  MDQPAVATAS TSIREDLVGG ESFITASKPA QKTSSFEREG WWRIALTDTP IPGTYHLKTF
    61  IEESLLNPVI ATYNFKNEGR KKPPLVQRNN PVLNDLPQYM PPDFLDLLKK QVATYSFKDK
   121  PRPSPSTLVD KDQSLQLSPG QYNVLPAPVP KYASRSCVFR STVQRFPTTY FIPHEGPGPG
   181  HYNVKMPPTS SVTSCFQSRV PRFLPSCSKT PGPGAYTTLR QFPKQSPTIA KMGQEHSLFF
   241  NNNNWLLK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against STPG4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.63
Highest tissue expression: 14 nTPM

Expression across tissuesHPA

Tissue

testis: 14 nTPM
gallbladder: 0.2 nTPM
bone marrow: 0.1 nTPM
choroid plexus: 0.1 nTPM
esophagus: 0.1 nTPM
heart muscle: 0.1 nTPM

Single-cell type

early spermatids: 64 nCPM
late primary spermatocytes: 50 nCPM
late spermatids: 47 nCPM
epicardial cells: 41 nCPM
oocytes: 28 nCPM
fibro-adipogenic progenitors: 23 nCPM

Immune cell

neutrophil: 0.3 nTPM
plasmacytoid DC: 0.3 nTPM
eosinophil: 0.1 nTPM
intermediate monocyte: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM

Brain region

hippocampal formation: 3.8 nTPM
amygdala: 3.6 nTPM
thalamus: 3.6 nTPM
medulla oblongata: 3.5 nTPM
cerebral cortex: 3.4 nTPM
pons: 3.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.14
gnomAD pLI: 0
DepMap mean gene effect: 0.06
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

epigenetic programing of male pronucleus
pyrimidine-containing compound catabolic process

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of STPG4 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

METTL23

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads STPG4 as an antibody target. Whether an autoantibody or antibody against STPG4 could matter depends on whether native STPG4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

STPG4 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label STPG4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...